VACCITECH (SP.ADR)/1 Market Cap ($20.62 Million)
Market Cap & Net Worth: VACCITECH (SP.ADR)/1 (2AB)
VACCITECH (SP.ADR)/1 market cap. VACCITECH (SP.ADR)/1 (F:2AB) has a market capitalization of $20.62 Million (€17.64 Million) as of November 4, 2026. Listed on the F stock exchange, this Germany-based company holds position #24866 globally and #2140 in its home market, demonstrating a 10.26% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying VACCITECH (SP.ADR)/1's stock price €0.51 by its total outstanding shares 40830353 (40.83 Million). Also see 2AB cash flow conversion for how efficiently the company converts equity into cash flow.
VACCITECH (SP.ADR)/1 Market Cap History (2021–2026)
VACCITECH (SP.ADR)/1 market cap history from 2021 to 2026. Data shows change from $427.23 Million to $29.36 Million (-46.18% CAGR). Check 2AB share price today for real-time trading data and today's change.
VACCITECH (SP.ADR)/1 Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how VACCITECH (SP.ADR)/1's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore VACCITECH (SP.ADR)/1 (2AB) equity growth momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
3.11x
VACCITECH (SP.ADR)/1's market cap is 3.11 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $427.23 Million | $268.00K | -$50.87 Million | 1594.13x | N/A |
| 2022 | $102.15 Million | $44.70 Million | $5.34 Million | 2.29x | 19.12x |
| 2023 | $154.66 Million | $802.00K | -$73.35 Million | 192.84x | N/A |
| 2024 | $46.54 Million | $14.97 Million | -$61.07 Million | 3.11x | N/A |
Competitor Companies of 2AB by Market Capitalization
Companies near VACCITECH (SP.ADR)/1 in the global market cap rankings as of November 4, 2026. Also see VACCITECH (SP.ADR)/1 asset portfolio for a full breakdown of the balance sheet.
Key companies related to VACCITECH (SP.ADR)/1 by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #180 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #372 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #411 globally with a market cap of $69.05 Billion USD ( AU$97.59 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #497 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #180 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $553.15 |
| #372 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $961.26 |
| #411 | CSL Ltd | AU:CSL | $69.05 Billion | AU$201.16 |
| #497 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $220.83 |
Market Capitalization of VACCITECH (SP.ADR)/1 (2021–2026)
Market capitalization of VACCITECH (SP.ADR)/1 from 2021 to today. Between 2021 and today, VACCITECH (SP.ADR)/1's market cap moved from $427.23 Million to $ 29.36 Million, with a yearly change of -46.18%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €29.36 Million | +9.82% |
| 2025 | €26.73 Million | -42.56% |
| 2024 | €46.54 Million | -69.91% |
| 2023 | €154.66 Million | +51.40% |
| 2022 | €102.15 Million | -76.09% |
| 2021 | €427.23 Million | -- |
End of Day Market Cap According to Different Sources
On Apr 24th, 2026 the market cap of VACCITECH (SP.ADR)/1 was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $20.62 Million USD |
| MoneyControl | $20.62 Million USD |
| MarketWatch | $20.62 Million USD |
| marketcap.company | $20.62 Million USD |
| Reuters | $20.62 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About VACCITECH (SP.ADR)/1
Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, focuses on developing immunotherapeutic drug candidates for treating auto-immune and inflammatory diseases. Its lead candidate is VTP-1000, which is in Phase 1 clinical trial to restore immune non-responsiveness to gluten in patients with celiac disease. The company is also developing VTP-300, an immunotherapeutic targetin… Read more